Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ArQule Inc. ARQL

Healthcare Biotechnology
Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range... see more

Recent & Breaking News (NDAQ:ARQL)

ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

Business Wire June 15, 2018

ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018

Business Wire June 14, 2018

The Race to Treat Cancer, ArQule Inc. Continues Progress Across All Pipeline Assets

GlobeNewswire June 11, 2018

Research Report Identifies Qudian Inc., ICICI Bank, Mobile TeleSystems OJSC, ArQule, Alibaba Group Holding, and Arcos Dorados with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire June 8, 2018

ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)

Business Wire June 7, 2018

ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018

Business Wire May 31, 2018

42 Biggest Movers From Friday

Benzinga.com  May 29, 2018

Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Benzinga.com  May 25, 2018

Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Benzinga.com  May 24, 2018

ArQule Strengthens Executive Team with Two Key Appointments

Business Wire May 24, 2018

Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Benzinga.com  May 23, 2018

Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Benzinga.com  May 18, 2018

ArQule Reports First Quarter 2018 Financial Results

Business Wire May 7, 2018

ArQule, Inc. to Host Earnings Call

Accesswire May 7, 2018

ArQule to Report First Quarter 2018 Financial Results on May 7, 2018

Business Wire April 23, 2018

32 Biggest Movers From Yesterday

Benzinga.com  April 18, 2018

27 Stocks Moving In Tuesday's Mid-Day Session

Benzinga.com  April 17, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  April 17, 2018

16 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  April 17, 2018

ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China

Business Wire April 17, 2018